Table 3.

Summary statistics for C_ss,ave in ng/mL for various ManNAc dosing regimens in subjects with GNE myopathy (N = 90)

ManNAc dose	Q8H for 30 days		Q12H for 30 days		Q24H for 30 days
	Median	5th–95th percentiles	Median	5th–95th percentiles	Median	5th–95th percentiles
Plasma ManNAc Css,ave (ng/mL)
3 g	922	501–1550	642	359–1060	365	223–570
4 g	1060	573–1790	729	404–1220	411	246–650
6 g	1290	692–2180	881	480–1480	483	281–780
10 g	1650	883–2810	1120	607–1900	603	340–989
Plasma Neu5Ac Css,ave (ng/mL)
3 g	633	247–2010	484	209–1420	338	174–825
4 g	702	265–2300	533	222–1610	364	181–921
6 g	818	296–2780	612	242–1930	405	190–1080
10 g	1020	344–3540	735	274–2440	464	204–1330

Dosing regimens: Q8H every 8 h, Q12H every 12 hours, Q24H once daily

C_ss,ave average drug concentration at steady state